West Pharmaceutical stock rises 2.71 percent after analyst upgrade
AD HOC NEWS
West Pharmaceutical stock gained 2.71% after Morgan Stanley upgraded its rating from Equal-Weight to Overweight and raised its price target from $365 to $400. The upgrade was driven by Morgan Stanley's belief that the company's Q2 revenue beat expectations, with EPS exceeding consensus estimates. Despite strong performance, the stock's high P/E ratio of 47.58 suggests limited room for future setbacks.
Read the full story
This is a short summary. The complete article is published by AD HOC NEWS.
Headline and summary aggregated from public news feeds. For information only — not financial advice.